Inclusion Criteria:  Patients willing and able to provide voluntary written informed consent and to follow the protocol specific requirements. Male or female patients over 18 years old. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected within 7 days prior to enrollment) who are admitted or being admitted to the hospital for a primary diagnosis of COVID-19. In the case of female patients of child-bearing potential, a negative blood pregnancy test prior to beginning the therapy. Patients intended to be hospitalized to receive SOC including dexamethasone treatment for COVID-19.  Exclusion Criteria:  Exclusion Criteria:  Patients with evidence of other serious infections. Malignancy.  Background disease which, in the opinion of the investigator prevents the patient from participating in the study such as:  Presence of serious chronic infectious. A condition resulting in immunodeficiency. Participants with glucose levels upon admission ≥ 250 mg/dL Acute psychosis Patients in a critical stage of COVID-19 disease that require mechanical ventilation. Pregnant and lactating women. Patients that are currently or have participated in other clinical studies with investigational drug, biological agent, or device within 1 month or within 5 half-lives (of the drug/biologic) prior to enrollment (whichever is longer). Patient currently receiving chemotherapy or immunosuppressive agents not including dexamethasone within 30 days before the screening.